Search Results

Robert J Lefkowitz and team's study 'GPCR signal transduction: β-arrestin activates ERK MAPK.' Dr. J. Silvio Gutkind.

Michel Bouvier, J Silvio Gutkind, and team found that Gαs is essential for GRK selectivity and gene regulation cardiometabolic diseases GPCR Events, Meetings, and Webinars October 2 - 3, 2023 | Celebrating Robert J.

work on Conformational dynamics underlying atypical chemokine receptor 3 activation Michael Trogdon, J Silvio Gutkind, Edward C Stites, et al., for their study on Systems modeling of oncogenic G-protein and

Chakit Arora, J Silvio Gutkind, and Francesco Raimondi for their work on The landscape of cancer-rewired

Next on the Dr. GPCR Podcast, we have Dr. Nicola Smith, Molecular Pharmacologist, lab head, and senior lecturer at UNSW Sydney. Subscribe to the podcast today and get notified when new episodes are released! Please share! https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ #gpcr #drgpcr #podcast

March 2022 "Congratulations to Richard J. Law, our newly named Chief Business Officer.

Silvio Gutkind.

Ines Liebscher, Ross Cheloha and Silvio Gutkind.

.; Tuisku, J. M.; Hirvonen, J. E. S.; Vahlberg, T.; Lahdenpohja, S.; Rinne, J. O.; Brück, A. E. J. Med. Der Wel, T.; Mandhair, H.; Honer, M.; Fingerle, J.; Scheffel, J.; Broichhagen, J.; Gawrisch, K.; Romero , J.; Hillard, C. .; Hénichart, J.-P.

.; Boström, J. J. Med. Chem.   2016 , 59  (10), 4443–4458. https://doi.org/10.1021/acs.jmedchem.5b01409 . .; Salvador Andresa, J.; Allongue, P.; Chazalviel, J.-N.; Gouget-Laemmel, A.   (3) Fan, J.; Toth, I.; Stephenson, R. J.

Wouters OJ, McKee M, Luyten J. J Health Econ. 2016;47:20-33. 8.            Lu S, He X, Ni D, Zhang J. Changeux J-P, Christopoulos A. J Phys Chem B. 2016;120(11):2878-85. 36.        

J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F. H., Pautsch, A., Steyaert, J., Weis, W. I., & Kobilka, B. K. (2011). M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. C., Gmeiner, P., Steyaert, J., Weis, W. I., Garcia, K. C., Wess, J., & Kobilka, B. K. (2013). Nature, 504(7478), 101–106. https://doi.org/10.1038/nature12735 Burg, J. S., Ingram, J.

Reference   Bikker, J. A., Trumpp-Kallmeyer, S., & Humblet, C. (1998). Carlsson, J., Yoo, L., Gao, Z. G., Irwin, J. J., Shoichet, B. K., & Jacobson, K. A. (2010). T., Baltos, J.-A., Thomas, T., Nguyen, T. D., Muñoz, L. L., Gregory, K. J., White, P. J., Sexton, P. M., Christopoulos, A., & May, L. T. (2016).

S., Sousa, J. B., Gonçalves, J., & Diniz, C. (2019). N., Castro, M., Wang, B., Bouley, R., Potts, J. T., Gardella, T. J., & Vilardaga, J. P. (2009). J. (2003). J., & Calebiro, D. (2016). J., & Calebiro, D. (2017).

Adapted from: Zhang Y, Tang H, Chen W, Zhang J. Int J Mol Sci. 2022 Aug 3;23(15):8625 . Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-Díaz R, Majellaro M, Tamhankar AV, Koenekoop L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán H,

References: Lyu, J. et al. AlphaFold2 structures guide prospective ligand discovery. Science https://doi.org/10.1126/science.adn6354 (2024) Abramson, J., Adler, J., Dunger, J. et al.

Int J Mol Sci. 2014 Feb 13;15(2):2554-72. Source: Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M. References Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M. Int J Mol Sci. 2014 Feb 13;15(2):2554-72. doi: 10.3390/ijms15022554.

, J. H.; Winkelman, J. , J.; Allen, R. J. J. Med.

J.; Graham, G. J., 2013). J., et al. 2010), which may ultimately compete with receptor antagonists, thereby decreasing the efficacy

antihistamines: A clinical trial is needed Jillian G Baker ,  Erica K Sloan ,   Kevin Pfleger ,  Peter J Trung Duong Nguyen ,  Ziaurrehman Tanoli ,  Saad Hassan , Umut Onur Özcan ,   Jimmy Caroli ,   Albert J physiological ligand complexes Luis P Taracena Herrera , Søren N Andreassen ,   Jimmy Caroli ,   Albert J a human bitter taste GPCR Lior Peri ,  Donna Matzov ,  Dominic R Huxley ,   Peter Gmeiner ,  Peter J

in-depth-molecular-profiling-of-an-intronic-gnao1-mutant-as-the-basis-for-personalized-high-throughput-drug-screening References Grimes, J. M., Medel-Lacruz, B., Baidya, M., Makarova, M., Mistry, R., Goulding, J., Drube, J., Hoffmann, C., Owen K., Selent, J., Hill, S. J., & Calebiro, D. (2023). Cell, 186(10), 2238–2255.e20. https://doi.org/10.1016/j.cell.2023.04.018 Janetzko, J., Kise, R., Barsi-Rhyne

Source: Kim J, Choi C. Cells. 2020 Feb 23;9(2):506. doi: 10.3390/cells9020506   Kim J, Choi C. Oct 19;46(10):11646-11664. doi: 10.3390/cimb46100691   Navarro G, Sotelo E, Raïch I, Loza MI, Brea J,

using the known structure of a homologous protein as a template to model the target protein ( Carlsson, J. References: Carlsson, J.  et al.  

References Barbazán J, Majellaro M, Martínez AL, Brea JM, Sotelo E, Abal M. Br J Pharmacol. 2020 Mar;177(5):978-991. doi: 10.1111/bph.14953. Sridharan R, Zuber J, Connelly SM, Mathew E, Dumont ME.

J. (2019). Volmat, V., & Pouysségur, J. (2001). Spatiotemporal regulation of the p42/p44 MAPK pathway. J. (2003).

Br J Pharmacol. 2023 Dec 12. doi: 10.1111/bph.16297.  Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M.

J., Benovic, J. L., Dohlman, H. G., Frielle, T., Bolanowski, M. A., Bennett, C. J., & Strader, C. D. (1986).

M., Stephany, J. J., & Fields, S. (2014). D., English, J. G., Coyote-Maestas, W., & Aashish Manglik. (2024).

J. B. Nibbs et al. 2013). Paing et al. 2022; J. L. J. Seaman 2012). J. al 2010) which may ultimately compete with receptor antagonists, thereby decreasing the efficacy (J.

J Biol Chem, 2018. 293(19): p. 7466-7473. 8.      J Biol Chem, 2007. 282(14): p. 10576-84. 13.